← ANALYST RATINGS · TIPRANKS
Enliven Therapeutics (ELVN): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $73.43, the highest $80.00, the lowest $68.00. The average is +96.8% from the last price of $37.32.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $41.00 → $40.00−2.4% | Hold | +7.2% | Reiterated | 14.10.26on TipRanks 20:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $39.00 → $38.00−2.6% | Hold | +1.8% | Upgrade | 14.10.26on TipRanks 20:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $41.00 → $39.00−4.9% | Hold | +4.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $42.00 → $41.00−2.4% | Hold | +9.9% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $40.00 → $39.00−2.5% | Hold | +4.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $40.00 → $38.00−5.0% | Hold | +1.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 07.10.26on TipRanks Oct 8 05:55 | −2.2%next day −1.3% · 5 days −4.0% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $78.00 | Buy | +109.0% | Reiterated | 07.10.26on TipRanks 03:55 | −2.2%next day −1.3% · 5 days −4.0% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 06.10.26on TipRanks 18:15 | −2.2%next day −1.3% · 5 days −4.0% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $70.00 | Buy | +87.6% | Initiated | 02.10.26on TipRanks 05:20 | +0.9%next day −3.9% · 5 days −13.9% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | $75.00 | Buy | +101.0% | Initiated | 01.10.26on TipRanks 05:10 | +0.6%next day +0.9% · 5 days −13.4% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $62.00 → $73.00+17.7% | Buy | +95.6% | Reiterated | 17.08.26on TipRanks 12:30 | +1.7%next day +1.6% · 5 days +3.9% | ↗ |
| Dara Azar★★★★★★★★★★#9877 · hits 33% · avg −5.2% | Stifel Nicolaus | $82.00 | Buy | +119.7% | Reiterated | 13.08.26on TipRanks 11:35 | −0.5%next day +1.5% · 5 days +3.4% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $60.00 → $70.00+16.7% | Buy | +87.6% | Assigned | 08.08.26on TipRanks Aug 7 07:30 | −0.3%next day −1.7% · 5 days −3.1% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | $60.00 → $75.00+25.0% | Buy | +101.0% | Reiterated | 06.08.26on TipRanks 09:30 | +1.1%next day −0.3% · 5 days −4.9% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $70.00 | Buy | +87.6% | Reiterated | 06.08.26on TipRanks 09:10 | +1.1%next day −0.3% · 5 days −4.9% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $55.00 → $68.00+23.6% | Buy | +82.2% | Assigned | 06.08.26on TipRanks 06:15 | +1.1%next day −0.3% · 5 days −4.9% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $80.00 → $78.00−2.5% | Buy | +109.0% | Reiterated | 05.08.26on TipRanks Aug 6 06:50 | −2.1%next day +1.1% · 5 days −3.3% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $67.00 → $80.00+19.4% | Buy | +114.4% | Assigned | 05.08.26on TipRanks Aug 6 06:20 | −2.1%next day +1.1% · 5 days −3.3% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $56.00 → $65.00+16.1% | Buy | +74.2% | Reiterated | 09.07.26on TipRanks 06:15 | +1.9%next day −2.5% · 5 days −2.4% | ↗ |
| Unknown Analyst | Jefferies | $59.00 | Buy | +58.1% | Reiterated | 15.06.26on TipRanks Jun 16 07:07 | −9.9%next day +1.0% · 5 days +17.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Enliven Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $74.00 at a price of $45.84 (+61.4%); now: $74.45 at $37.32 (+99.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 2 | 0 | 2 |
| Buy | 18 | 15 | 12 | 13 | 9 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.45 (from $-0.54 to $-0.38). Last quarter: $-0.49.
Best top-analyst consensus in the sector · Healthcare
About Enliven Therapeutics
- CEO: Richard A. Fair
- Employees: 67
- 6200 Lookout Road, Boulder, CO, 80301, US
- www.enliventherapeutics.com
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Data from the stock’s TipRanks forecast page, read 29 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗